Hypertension scientists may have found a new cause of high blood pressure — what does it mean and how could it change treatment

Hypertension scientists may have identified a new brain-based cause of high blood pressure, according to a study published in April 2026 in the journal Circulation Research, potentially opening a pathway to treatments beyond standard antihypertensive drugs. Researchers from the University of São Paulo and the University of Auckland found that the lateral parafacial (pFL) region in the brainstem can drive increased sympathetic nerve activity, with experiments showing that activation of these neurons constricts blood vessels and raises blood pressure, while their inhibition returns levels to normal in controlled animal models.

The findings are significant as hypertension affects around one-third of the global population, with up to 40 percent of patients remaining uncontrolled despite medication, and an estimated 50 percent of cases involving a neurogenic component. The study also points to a potential treatment strategy by targeting carotid body sensors to regulate this brain pathway indirectly, although confirmation in human studies is still required. The WP Times reports this, citing ScienceAlert and peer-reviewed findings published in Circulation Research.

What new cause of hypertension did scientists discover in the brain

The research, conducted by teams at the University of São Paulo and the University of Auckland, focused on how the brain regulates breathing and blood pressure simultaneously. The lateral parafacial (pFL) region, already known for controlling forceful breathing patterns such as coughing or exercise-related exhalation, was found to have a second critical function: controlling blood vessel constriction. In laboratory tests on rats, scientists used genetic tools to switch pFL neurons on and off. When activated, these neurons triggered a cascade of signals through the sympathetic nervous system — the body’s “fight-or-flight” response — causing blood vessels to tighten and blood pressure to rise. When the same neurons were deactivated, blood pressure dropped back to normal levels.

“Given that around 50 percent of patients with hypertension have a neurogenic component, the challenge is to understand mechanisms generating sympatho-excitation,” researchers wrote (Circulation Research, 2026). This confirms that the brain plays a central role in many hypertension cases, not just the heart or kidneys. The findings also explain why some patients do not respond fully to standard antihypertensive drugs: these medications often target hormones or blood vessels directly, but not the neural signals that may be driving the condition.

How breathing, sleep and the nervous system affect high blood pressure

One of the most important aspects of the study is the link between breathing patterns and blood pressure regulation. The pFL region becomes particularly active under conditions of low oxygen or high carbon dioxide — situations commonly seen in sleep apnoea.

This helps explain a well-documented clinical pattern: patients with sleep apnoea are significantly more likely to develop hypertension. During episodes of disrupted breathing at night, oxygen levels drop and carbon dioxide rises, activating pFL neurons and increasing sympathetic nerve activity. This leads to repeated spikes in blood pressure over time. Julian Paton, physiologist at the University of Auckland, described the mechanism clearly: “We discovered that, in conditions of high blood pressure, the lateral parafacial region is activated and when we inactivated it, blood pressure fell to normal levels” (Paton, research statement, 2026).

This breathing–brain–blood pressure loop suggests that hypertension is not only a cardiovascular condition but also a neurological and respiratory one. It reinforces the need for integrated treatment approaches that consider sleep quality, дыхание и нервную систему.

What new treatments for hypertension could emerge from this discovery

The study does not only identify a cause — it also proposes a potential treatment strategy. Instead of targeting the brain directly, which can be complex and risky, researchers are exploring ways to control the pFL region indirectly through the carotid bodies. These small sensory organs located in the neck monitor oxygen and carbon dioxide levels in the blood. By influencing these sensors, scientists believe they can regulate the activity of pFL neurons without needing drugs to penetrate the brain.

“Our goal is to target the carotid bodies… to inactivate remotely the lateral parafacial region safely,” Paton explained (University of Auckland, 2026). This approach could lead to new classes of hypertension treatments, particularly for patients whose condition is driven by neural mechanisms. However, the researchers emphasise that the work is still at an early stage and has so far been tested only in animal models.

Key data on hypertension risk factors from recent studies

Alongside the brain-based findings, separate research from the nuMoM2b Heart Health Study highlights how other factors contribute to hypertension, particularly in women after pregnancy.

“These findings highlight pregnancy and the postpartum period as an opportunity to optimise cardiometabolic health,” researchers noted (JAMA Cardiology, April 2026).

Practical insights: what this means for patients with hypertension

• Brain mechanisms may explain why treatment does not work for some patients
• Breathing disorders such as sleep apnoea can directly increase blood pressure
• Weight (BMI) remains the strongest modifiable risk factor
• Postpartum monitoring is critical for early detection in women
• Future treatments may target neural pathways, not just blood vessels

Key questions on hypertension: what the new research shows

Recent findings suggest that some cases of hypertension may be driven by mechanisms in the brain rather than by vascular or hormonal factors alone. The research focuses on how specific neural pathways influence blood pressure regulation and why this may explain treatment resistance in a proportion of patients. Below are the key questions with evidence-based, practical answers.

What exactly have scientists identified as a new cause of hypertension?
Researchers have identified the lateral parafacial (pFL) region in the brainstem as a potential contributor to elevated blood pressure. Activation of neurons in this area increases sympathetic nervous system activity, leading to vasoconstriction and a rise in blood pressure.
Practical relevance: this indicates that, in some patients, hypertension may be driven by neural signalling rather than solely by vascular dysfunction.

Why is this finding important for patients with high blood pressure?
It provides a plausible explanation for why a significant proportion of patients do not achieve adequate control with standard antihypertensive therapies. Estimates suggest that up to 50% of cases may involve a neurogenic component.
Practical relevance: management may need to consider factors beyond medication, including sleep quality and autonomic regulation.

How robust is the current evidence?
The findings are based on controlled experimental studies in animal models. Activation and inhibition of pFL neurons produced measurable changes in blood pressure. However, confirmation in human studies is still required.
Practical relevance: the results are scientifically significant but not yet sufficient to change clinical practice.

What is the link between breathing and hypertension in this research?
The pFL region is involved in respiratory control and responds to changes in oxygen and carbon dioxide levels. Under conditions such as sleep apnoea, this response can increase sympathetic activity and elevate blood pressure.
Practical relevance: untreated sleep-disordered breathing may contribute to persistent hypertension and should be clinically assessed where suspected.

Could this discovery lead to new treatments?
The research suggests that targeting the carotid bodies — peripheral sensors that influence the pFL region — may offer a way to regulate blood pressure indirectly without acting on the brain itself.
Practical relevance: this represents a potential future treatment pathway, subject to further clinical development and testing.

Does this change the role of established risk factors such as weight and genetics?
No. Current evidence continues to show that elevated body mass index is a major modifiable risk factor, while genetic predisposition contributes to risk but to a lesser extent in population studies.
Practical relevance: established risk management strategies, particularly weight control, remain central.

What should patients do in light of this research?
There is no immediate change to clinical recommendations. However, the findings reinforce the importance of comprehensive risk management.
Practical relevance:

• maintain a healthy body weight
• monitor blood pressure regularly
• seek assessment for sleep apnoea if symptoms are present
• follow prescribed treatment plans

This approach remains consistent with current medical guidance while research into neural mechanisms of hypertension continues.

Read about the life of Westminster and Pimlico district, London and the world. 24/7 news with fresh and useful updates on culture, business, technology and city life: UK Border Revolution 2026: Mandatory Electronic Travel Authorisation (ETA) Enforcement and the End of Non-Digital Entry